Capricor Reports Q3 2026 Financial Results and HOPE-3 Clinical Trial Data
Capricor (CAPR) reported a third-quarter net loss of $42.7 million, or $0.73 per share, driven by increased research and development costs and manufacturing scale-up activities in preparation for the potential commercial launch of deramiocel. Despite the widening loss, the company maintains a strong liquidity position with $198.5 million in cash and marketable securities, which management expects to fund operations for at least 12 months. Clinically, Capricor highlighted positive results from its HOPE-3 trial, noting a 1.1 point absolute difference in the Performance of the Upper Limb (PUL 2.0) scale compared to placebo. The company is also expanding manufacturing capacity in San Diego to support an annual patient load of up to 2,500. All eyes remain on the upcoming FDA PDUFA action date scheduled for November 22, 2026.
Tickers: $CAPR
Topics: biotechnology clinical trial results earnings report net loss workforce reduction